Why CPAP and tirzepatide make good bedfellows: 2024 sleep conference highlights

What the latest evidence says about obstructive sleep apnoea, weight loss and cardiometabolic health
5
24 October 2024
Save

This content has been independently produced by AusDoc, made possible through sponsorship from Eli Lilly

Numerous research studies have focused on how sleep behaviour and more specifically, obstructive sleep apnoea (OSA) impacts cardiometabolic risk, so it was unsurprising that this was one of the underlying themes at this year’s 35th annual scientific meeting of the Australasian Sleep Association and the Australian and New Zealand Sleep Science Association.

Report

Harassment or bullying behavior
Contains mature or sensitive content
Contains misleading or false information
Contains abusive or derogatory content
Content that breaches the privacy of other individuals
Contains spam, fake content or potential malware

Block Member?

Please confirm you want to block this member.

You will no longer be able to:

  • See blocked member's posts
  • Mention this member in posts
  • Message this member
  • Add this member as a connection

Please note: This action will also remove this member from your connections and send a report to the site admin. Please allow a few minutes for this process to complete.

Report

You have already reported this .